Literature DB >> 29770283

Cardiac Amyloidosis Diagnosis with Magnetic Resonance Imaging: A Case Report.

Meidi El Issa1, Malik El Issa2, Besma Sidia1.   

Abstract

Amyloidosis is a rare disease, which can affect various organs, such as the kidneys, heart, liver, respiratory and gastrointestinal tracts, and the nervous system. It still has a bad prognosis nowadays, despite chemotherapy and the new biotherapies. Its physiopathology corresponds to an irreversible, extracellular accumulation of fibrillous proteins in the tissues. Notwithstanding the fact that a clear diagnosis can be made with histology (of solid injured organs or a subcutaneous biopsy), magnetic resonance imaging (MRI) can show various advantages, especially to prove cardiac involvement, with great specificity and sensibility as well. Consequently, the MRI's place can be considered a cornerstone of the diagnosis; more so because biopsies are not routine and easy procedures. Moreover, amyloidosis includes several symptoms, which are sometimes tricky, so the clinician should swiftly consider the usefulness of MRI to get the patient well-oriented and treated.

Entities:  

Keywords:  cardiac amyloïdosis; enhancement; left ventricle; mri; protein; right ventricle

Year:  2018        PMID: 29770283      PMCID: PMC5953506          DOI: 10.7759/cureus.2330

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

1.  Congestive heart failure: a diagnostic approach in cardiac amyloidosis. Role for cardiac magnetic resonance imaging.

Authors:  Alessandro Cuneo; Johannes Brockmeier; Karin Klingel; Reinhard Kandolf; Ulrich Tebbe
Journal:  Herz       Date:  2006-12       Impact factor: 1.443

Review 2.  MRI of hypertrophic cardiomyopathy: part 2, Differential diagnosis, risk stratification, and posttreatment MRI appearances.

Authors:  Mark W Hansen; Naeem Merchant
Journal:  AJR Am J Roentgenol       Date:  2007-12       Impact factor: 3.959

3.  Magnetic resonance imaging in cardiac amyloidosis.

Authors:  Dudley J Pennell; Alicia M Maceira
Journal:  JACC Cardiovasc Imaging       Date:  2009-12

4.  Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy.

Authors:  R Fattori; G Rocchi; F Celletti; P Bertaccini; C Rapezzi; G Gavelli
Journal:  Am Heart J       Date:  1998-11       Impact factor: 4.749

5.  Cardiac amyloidosis: typical imaging findings and diffuse myocardial damage demonstrated by delayed contrast-enhanced MRI.

Authors:  Eijun Sueyoshi; Ichiro Sakamoto; Tomoaki Okimoto; Kuniaki Hayashi; Kyouei Tanaka; Genji Toda
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Jul-Aug       Impact factor: 2.740

6.  Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance.

Authors:  E Perugini; C Rapezzi; T Piva; O Leone; L Bacchi-Reggiani; L Riva; F Salvi; L Lovato; A Branzi; R Fattori
Journal:  Heart       Date:  2005-06-06       Impact factor: 5.994

Review 7.  Amyloidosis of the heart and respiratory system.

Authors:  Filiep Van Geluwe; Steven Dymarkowski; Ilse Crevits; Walter De Wever; Jan Bogaert
Journal:  Eur Radiol       Date:  2006-05-16       Impact factor: 5.315

8.  MR findings in cardiac amyloidosis.

Authors:  Rohan I vanden Driesen; Richard E Slaughter; Wendy E Strugnell
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

9.  Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects.

Authors:  Gabriele A Krombach; Christa Hahn; Maren Tomars; Arno Buecker; Armin Grawe; Rolf W Günther; Harald P Kühl
Journal:  J Magn Reson Imaging       Date:  2007-06       Impact factor: 4.813

10.  Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy.

Authors:  Holger Vogelsberg; Heiko Mahrholdt; Claudia C Deluigi; Ali Yilmaz; Eva M Kispert; Simon Greulich; Karin Klingel; Reinhard Kandolf; Udo Sechtem
Journal:  J Am Coll Cardiol       Date:  2008-03-11       Impact factor: 24.094

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.